Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically—tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.
Get full access to this article
View all access options for this article.
References
1.
David BootheW, TarboxJA, TarboxMB. Atopic dermatitis: pathophysiology. In: FortsonEA, FeldmanSR, StrowdLC, eds. Management of Atopic Dermatitis: Methods and Challenges. Advances in Experimental Medicine and Biology. Springer International Publishing; New York City, NY. 2017:21–37.
2.
FurueM, ChibaT, TsujiG, et al.Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int, 2017; 66(3):398–403.
3.
BeckLA, ThaçiD, HamiltonJD, et al.Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med, 2014; 371(2):130–139.
4.
SimpsonEL, PallerAS, SiegfriedEC, et al.Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol, 2019; 156(1):44–56.
GrabbeS, BeissertS, EnkA.Systemic immunosuppression in times of COVID-19: do we need to rethink our standards?. J Dtsch Dermatol Ges, 2020; 18:810–813.
7.
PallerAS, SiegfriedEC, ThaçiD, et al.Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol, 2020; S0190-9622(20)31152-X.
8.
FutamuraM, LeshemYA, ThomasKS, et al.A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol, 2016; 74(2):288–294.
9.
TofteS, GraeberM, CherillR, et al.Eczema Area and Severity Index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol, 1998; 11:S197.
10.
BożekA, ReichA. Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology, 2017; 233(1):16–22.
11.
YosipovitchG, ReaneyM, MasteyV, et al.Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol, 2019; 181(4):761–769.
12.
LudwigCM, KraseJM, PriceKN, et al.A practical guide for transitioning from classical immunosuppressants to dupilumab in atopic dermatitis. J Dermatolog Treat, 2019; 1–4.
13.
WollenbergA, BarbarotS, BieberT, et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol, 2018; 32(6):850–878.
14.
SidburyR, DavisDM, CohenDE, et al.Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol, 2014; 71(2):327–349.
DvorakovaV, O'ReganGM, IrvineAD. Methotrexate for severe childhood a topic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol, 2017; 34(5):528–534.
ClinicalTrials.gov. Study to assess the safety and efficacy of lebrikizumab (LY3650150) in adolescent patients with moderate-to-severe atopic dermatitis—full text view. Available at: https://clinicaltrials.gov/ct2/show/NCT04250350. Accessed July3, 2020.
